Clinical Trial Update: Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 window-of-opportunity trial evaluating pembrolizumab alone and in combinations in bladder cancer; results were posted on 2025-10-07.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Keytruda (Pembrolizumab) (pembrolizumab)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Bladder Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-10-07